TY  - JOUR
AU  - Mai, Elias K
AU  - Hielscher, Thomas
AU  - Bertsch, Uta
AU  - Salwender, Hans J
AU  - Zweegman, Sonja
AU  - Raab, Marc S
AU  - Munder, Markus
AU  - Pantani, Lucia
AU  - Mancuso, Katia
AU  - Brossart, Peter
AU  - Beksac, Meral
AU  - Blau, Igor W
AU  - Dürig, Jan
AU  - Besemer, Britta
AU  - Fenk, Roland
AU  - Reimer, Peter
AU  - van der Holt, Bronno
AU  - Hänel, Mathias
AU  - von Metzler, Ivana
AU  - Graeven, Ullrich
AU  - Müller-Tidow, Carsten
AU  - Boccadoro, Mario
AU  - Scheid, Christof
AU  - Dimopoulos, Meletios A
AU  - Hillengass, Jens
AU  - Weisel, Katja C
AU  - Cavo, Michele
AU  - Sonneveld, Pieter
AU  - Goldschmidt, Hartmut
TI  - Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
JO  - Leukemia
VL  - 38
IS  - 3
SN  - 0887-6924
CY  - London
PB  - Springer Nature
M1  - DKFZ-2023-02577
SP  - 640-647
PY  - 2024
N1  - 2024 Mar;38(3):640-647
AB  - Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005-2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both. Patients were divided in a training (n = 1333) and three validation cohorts (n = 2367). During IT, 11.8
LB  - PUB:(DE-HGF)16
C6  - pmid:38062124
DO  - DOI:10.1038/s41375-023-02105-6
UR  - https://inrepo02.dkfz.de/record/285996
ER  -